Objective: Prior hypothesis-driven studies identified immunophenotypic characteristics associated with the control of HIV replication without antiretroviral therapy (HIV controllers) as well as with the degree of CD4 þ T-cell recovery during ART. We hypothesized that an unbiased 'discovery-based' approach might identify novel immunologic characteristics of these phenotypes.
Introduction
The vast majority of HIV-infected adults who have access to combination antiretroviral therapy (ART) and are motivated to take these drugs can achieve and maintain undetectable plasma HIV RNA levels (viral load). As a consequence of treatment-mediated viral suppression, peripheral CD4 þ T-cell counts increase, and AIDSrelated complications are largely prevented. Although most patients taking ART achieve virologic suppression, a substantial (approximately 15-30%) but poorly described subset of treated adults maintain abnormally low peripheral blood CD4 þ T-cell counts ('immunologic nonresponders') [1, 2] . We define an immunologic nonresponder as an individual whose on-therapy CD4 þ T-cell count plateaus to a level < 350 cells/ml despite being aviremic. A low on-therapy CD4 þ T-cell count has been associated with increased risk of serious non-AIDS events, including heart disease and cancer, as well as an increased risk of mortality [3] [4] [5] . Understanding how immunologic responders and nonresponders differ at a more granular level in terms of precise patterns of immune function will be critical in identifying targets for therapeutic interventions that may augment or optimize ART delivery.
In parallel with ongoing advances in ART agents and ART delivery strategies, there is a large and interest in identifying 'curative' interventions [6] . Optimism that a cure might be feasible is driven in part by the fact that a small proportion of HIV-infected adults are able to control HIV indefinitely in the absence of ART. The majority of these so-called 'HIV controllers' harbor replication-competent virus yet exhibit durable viral control, normal, or very slowly declining CD4 þ T-cell counts, and have low risk for AIDS-related morbidity. Controllers -particularly those who also maintain low levels of immune activation -are now being studied in detail as they may provide clues as to how to effectively control HIV infection [7] .
To more fully characterize immunologic features seen in varying states of 'aviremia'--mediated by ART for those on treatment and presumably mediated by host mechanisms for those not on treatment--we assembled a cohort of four unique groups from patients enrolled in two longitudinal HIV patients cohorts at University of California, San Francisco (UCSF) who have undetectable HIV RNA levels: HIV controllers, immunologic responders, immunologic nonresponders, and as a control group HIV-uninfected individuals. T-cell activation, senescence, maturation, and function were measured using well validated assays generating over 514 Boolean subpopulations. Because there were many more parameters, p, than observations, n, and the parameters were highly correlated it was necessary to reduce the parameter space in a systematically unbiased way. Recent advances in machine learning have been developed to deal with the so-called 'P >> n problem' [8] . Recursive feature elimination random forests [9] , conditional random forests [10, 11] , and fuzzy forests have been shown to produce relatively unbiased variable importance lists in these types of settings. Using data-mining approaches and complex multiparameter immunophenotypic data, we sought to identify immunologic signatures associated with each of the above four clinical phenotypes. We report here several novel correlates to each phenotype, which may have implications for future therapeutic strategies.
Methods

Study participants
All participants were enrolled in one of two longitudinal cohorts based at the UCSF: the Options Project (which enrolls individuals diagnosed with acute/early HIV infection and at-risk HIV-uninfected controls) and the Study on the Consequences of the Protease-Inhibitor Era cohort (which enrolls individuals with chronic HIV infection, and HIV-negative controls). Cryopreserved peripheral blood mononuclear cells were stored and sent in batch to the UCSF Core Immunology Laboratory for advanced immunophenotyping (see below). All immunologic data were assembled in a single database. We selected four unique groups: HIV controllers: persons with documented HIV-1 infection for at least 1 year, ART-naive and with a plasma HIV RNA level < 40-75 copies RNA/ml for all visits (n ¼ 98), immunologic responders: individuals with chronic HIV who achieved durable viral suppression (plasma HIV RNA < 40-75 copies/RNA, larger blips were allowed if they were flanked by undetectable values) on a stable ART regimen and who had high CD4 þ T-cell counts (>350 cells/ml, n ¼ 142), immunologic nonresponders: individuals with chronic HIV who achieved durable viral suppression (plasma HIV RNA < 40-75 copies/RNA) on a stable ART regimen but whose CD4 þ T-cell counts plateaued to a level < 350 cells/ml, n ¼ 59), and HIV-negative controls (n ¼ 43).
Measurements
Immunophenotypic parameters of T-cell maturation (CD45RA, CCR7, CD27, and CD28), activation (CD38, HLA-DR, and CCR5), dysfunction (PD-1), senescence (CD57), HIVand/or CMV (ex vivo) antigenspecificity (IFNg, TNFa, IL-2, and CD107a) and proliferation [carboxyflourescein succinimidyl ester (CFSE)] were measured on peripheral blood mononuclear cells from all participants, using previously described methods [12, 13] . Digital Supplemental Table 1 , http://links.lww.com/QAD/A885 lists all of the potential parameters.
Statistical methods
Data on 514 unique immunologic profiles were generated on each individual subject. Owing to the complex nature of the data, we employed several machine learning techniques to fulfill our objectives. Because variables such as CD4 þ T-cell count and viral load were used to define the groups, these variables were left out of all machine learning analyses.
We used a variant of random forests, fuzzy forests [14, 15] , which are random forests with recursive feature elimination (RFE) and variable importance that are done on individual modules created using weighted gene coexpression network analysis. We briefly review random forests. Random forests are a supervised learning method, meaning the outcome labels (in this case the clinical phenotypes) are used to classify the observations into categories [16] . Random forests are useful in the so-called 'large p, small n problem' wherein one has more potential predictors than observations. These methods have an advantage over other machine learning algorithms in that they incorporate high-order interactions, are largely unbiased even in the case of different scales among the predictor variables, have a natural variable importance measure, and are expedient even in very large datasets.
Random forests are an ensemble of individual classification and regression trees. The data are bootstrapped and a tree is built on each bootstrap sample. To reduce the correlation between trees, at each node the number of variables chosen at each node is of size 'mtry.' For example, if mtry is 5, then 5 predictors are randomly selected from all possible predictors, P, at each node. The usual default for mtry is the square root of P. The best splitter in terms of the Gini index is chosen from this set to split the sample. Each tree is grown out and not pruned. The observations that are not in each individual tree (about 33% of the data) are called the out-of-bag (OOB) sample. The OOB predictive error can be estimated by predicting the outcome by a majority rules vote involving trees in the forest that did not have that observation in the training sample. Because of these features, there is low correlation among the individual trees. By averaging over a large number of trees, this learner has both low bias and low variance. This type of ensemble predictor is attractive because it is invariant to monotonic transformations, can handle large number of variables and is robust to outliers. These features are very amenable for flow-cytometry data in that it handles highly skewed variables without any need to symmetrize skewed variable distributions. The more trees in the forest, the more accurate the ensemble [16] . All analyses were conducted in R and Cþþ. This approach has been previously used for gene filtering in microarrays [9, [17] [18] [19] [20] .
To select the approximately 50 most important parameters using fuzzy forests, we used the wff option in fuzzy forests. This option is used to account for the network structure among the predictors. First modules are constructed using weighted gene coexpression network analysis. This creates modules that have higher correlation within module than between [21] . For each module, we then fit RFE-random forest [22] [23] [24] [25] [26] [27] [28] and then ranked the predictors using permutation importance [10, [29] [30] [31] . After each iteration we discarded the variables with the smallest variable importance retaining the set of parameters that has the smallest OOB rate. It is important to note that the OOB error rate for this part is used only for variable selection, and not to obtain an estimate of the error rate. This iterative procedure has been shown to yield good stability [9] . For each iteration we grew 50 000 trees. The survivors of this process for each module were then pooled and another RFE-random forest was performed. This was done until we had a set of approximately 50 features. We tried several values of 'mtry' with similar results.
Unsupervised learning was performed using hierarchical clustering and a random forest dissimilarity matrix. In this analysis, the clinical phenotype (the clinical group the subject is in) as well as CD4 þ T-cell counts and viremia were excluded from the analysis.
Results
We performed immunophenotyping on 342 individuals from four unique 'aviremic' clinical phenotypes: HIV controllers (n ¼ 98), immunologic nonresponders (n ¼ 59), immunologic responders (n ¼ 142), and HIV-negative controls (n ¼ 43). Most HIV-positive participants were men between 40-55 years old; HIV-negative controls were slightly younger ( Table 1) . Although the median CD4 þ T-cell count was 235 cells/ mm 3 in the immunologic nonresponders, the median CD4 þ T-cell count was well above 500 cells/ml for each of the other groups.
We obtained data on the level of T-cell maturation (CD45RA, CCR7, CD27, and CD28), activation (CD38, HLA-DR, and CCR5), dysfunction (PD-1), senescence (CD57), and functional capacity (cytokine production in response to HIV or CMV peptide pools) and T-cell proliferation (CFSE). There were 514 measurements included in the analysis (Supplemental Table 1 , http://links.lww.com/QAD/A885). Variables, including absolute CD4 þ and CD8 þ T-cell counts, the CD4 þ /CD8 þ ratio, nadir CD4 þ count, and viral load measures were excluded because they were used to define the four clinical phenotypes.
Identification of five unique immunologic clusters using unsupervised learning
We first used unsupervised hierarchical clustering using a random forest dissimilarity matrix to identify groups of HIV-infected participants that shared related immunologic signatures when the clinically-defined groups (controllers, immunologic responders/nonresponders) were not specified a priori. CD4 þ T-cell counts, viral load, and any group-defining characteristics were not included in the analysis. As shown in Fig. 1 , five unique clusters were identified (labeled A-E), two of which were highly enriched for HIV controllers and two that were highly enriched for immunologic nonresponders. Immunologic responders clustered together and are identified by cluster D. Variables that distinguished the clusters included Gag-specific CD4 þ and CD8 þ T cells, HLA DRþ central memory T cells, resting CD4 þ central memory cells, central memory-activated CD8 þ T cells, perforin positive cells and PD-1.
Overall HIV controllers had higher percentages of Gag-specific CD4 þ and CD8 þ T cells relative to the other groups. Controllers also had much lower percentages of central memory CD4 þ T cells that express HLA-DR. There were two distinct clusters of controllers which we labeled cluster A and cluster B in Fig. 1 . Controller cluster B had higher percentages of CD8 þ T cells that are CD28ÀCD57þ (19.7 versus 26.7%, respectively, P ¼ 0.0078 by the t test comparing cluster A and B) as well as higher percentages of CD8 þ HLA-DRþ cells (39 versus 48.9%, P ¼ 0.014) than controller cluster A. Controller cluster A had higher percentages of CD8 þ cells that were RAþ (61.9 versus 51.6%, P ¼ 0.0025) and higher percentages of CD8 þ HLADRþCCR7À that are CD38þ (55.3 versus 38.8%, P ¼ 0.0068) compared to cluster B. Similarly cluster A had higher percentages of CD8 þ cells that were RAþCCR7þCD27þCD28þ 57À than cluster B (26.4 versus 15.1%, P < 0.0001). Conversely, cluster B had higher percentages of CD8 þ cells that were RAþCCR7ÀCD27ÀCD28-57þ (7.7 versus 11.97%, P ¼ 0.0001). This perhaps suggests that the enrichment for RAþ cells appears to be driven mainly by naive CD8 þ T cells and not effector memory RAs (TEMRAs) (CD8 þ CCR7ÀCD45RAþ) in cluster A. Cluster B had slightly more study participants who self-reported black ethnicity, but this did not reach statistical significance.
Immunologic nonresponders had higher levels of CD4 þ activation (CD38þ HLA-DRþ) as well as higher percentages of cells that expressed PD-1 compared to the other groups. There were also two distinct immunologic nonresponder clusters, clusters C and E. Although both clusters of immunologic nonresponders were characterized by high levels of both CD4 þ and CD8 þ T-cell activation and PD-1 expression, immunologic nonresponder cluster E appeared to be distinct from all of the other clusters and was characterized by lower percentages of activated CD8 þ T cells that are CCR5þ (60.7 versus 44.3%, P ¼ 0.0068) and higher percentages of central memory CD4 þ T cells than Immunologic NonResponder cluster C (28.6 versus 33.9%, P ¼ 0.0013).
Correlates of HIV control using supervised learning
We next used fuzzy forests to identify the most important immunologic characteristics that predict each clinically defined group. We compared the HIV controllers to the immunologic responders, as both groups were distinguished by having a relatively intact immune system, with the groups differing primary based on the mechanism by which HIV was controlled (host-mediated control versus antiretroviral treatment).
The best predictors are given in the variable importance plot for responders versus controllers (Fig. 2a ). The predictors are ranked with the best predictor at the top. As expected, we found that compared to the immunologic responders, HIV controllers had much higher levels of 1556 AIDS 2016, Vol 30 No 10 polyfunctional (ex vivo) Gag-specific CD4 þ and CD8 þ T cells than the other groups. This was particularly true for the frequency of polyfunctional (CD107þ, IFNgþ, IL-2þ, TNFaþ) CD4 þ and CD8 þ T cells. There were also marked differences in activation markers particularly HLA-DR and differences in central memory T cells ( Table 2 lists post hoc t test P values for the most important variables).
The percentage of 'activated' (CD38þ HLA-DRþ) CD8 þ T cells was higher in controllers than in other groups (a median of 27% in controllers, versus 24% in nonresponders, 21% in ART responders, and 11% in HIV negatives), an observation that is consistent with prior studies from this and other cohorts [32] [33] [34] . Compared to responders controllers have lower percentages of CD4 þ naive cells that are HLA-DR positive (1.56 versus 3.73%, P < 0.0001), lower percentages of CD4 þ central memory T cells that are DR positive (9.89 versus 15.51%, P < 0.0001) and lower percentages of CD4 þ effector memory cells that are HLA-DRþ (15.43 versus 12.93%, P < 0.0001).
Correlates of immunologic response during antiretroviral therapy using supervised learning
We also used the supervised learning approach to identify unique signatures associated with a low CD4 þ T-cell count while on ART (immunologic nonresponder versus responder). Figure 2b shows the most important variables in predicting immunologic nonresponse and Table 3 lists the post hoc P values in comparing nonresponders and responders on these variables. One of the most notable immunological differences that uniquely identified this group is the expression of PD-1 on CD4 þ T cells and CD4 þ T-cell subsets, a finding consistent with prior observations from this cohort [26] . Immunologic nonresponders had higher frequencies of TNFaþ and INFgþ CD4 þ cells compared to responders. Nonresponders also had higher percentages of CD4 þ T-cell activation in all subsets (naïve, central memory, and effector memory) and lower frequencies of naive CD4 þ T cells than responders (see Table 3 ).
Predictive capacity of the model Overall, the forests had excellent predictive accuracy. Because using the OOB error rate on iterated sets can lead to biased estimates of the true error rate, we used the original 0.632 þ bootstrap method to estimate the error rate. The overall OOB error rate was approximately 11% for each comparison meaning that, on average, 11% of the participants were misclassified. Moreover, the low OOB error rate suggests that the results may be generalizable to other cohorts.
Using random forests-type algorithms, we did not explicitly control for age or any other variable. Age was not listed as one of the top predictors and hence was not included as a potential predictor in the final random forest. Of note, HIV-negative individuals were significantly younger than the other three groups. However, the three HIV-infected groups did not differ significantly in age (P ¼ 0.1348 by the F test). When age was included into the top 50 variables and random forests were run and conditional variable importance results generated, age was again not selected as one of the most important variables in terms of classifying participants.
Discussion
The overall objective of our analysis was to find, in an unbiased manner, the key immunologic signatures associated with three distinct clinical phenotypes: HIV controllers, immunologic nonresponders, and immunologic responders. Using sophisticated machine-learning techniques designed to find novel observations within complex datasets where the number of parameters is much larger than the number of observations, we were able to meaningfully sort through the data in a systematic manner. The algorithm found a very strong and Immunophenotypes in aviremic HIVR adults Ramirez et al. 1559 Table 3 . P values obtained via the univariate t-test for the most important variables in predicting responders versus immunologic nonresponders as given by fuzzy forests. predictive signal, with an overall misclassification across the three HIV-seropositive groups and the HIVseronegative group of approximately 11%. This unbiased approach confirmed a number of prior observations, and identified several unique associations that might lead to novel therapeutic approaches aimed at either controlling HIV in the absence of therapy ('functional' cure) or enhancing immune reconstitution during therapy. Importantly, these variable importance lists are not simply univariate tests of importance similar to a t test, but rather allow for interaction of the variables. We also show excellent predictive capacity of the model. The low 'Out-of-Bag' error rate suggests that these results may be generalizable to other cohorts.
The study confirmed a number of prior observations; specifically we found that HIV controllers have higher levels of HIV-specific T cells and higher levels of CD8 þ T-cell activation [35] [36] [37] [38] [39] [40] , while identifying unique immunophenotypes that differentiate these different HIV participant groups. For example, we identified a unique cluster of HIV controllers who maintained low CD8 þ T-cell activation levels despite robust HIV-specific T-cell responsiveness. Nonresponders clustered in to two groups. One of these groups (group E), in particular was distinct in that it had, on average, lower percentages of activated CD8 þ T cells that expressed CCR5 and higher percentages of central memory CD4 þ T cells. These novel associations are the advantage of using a discoverybased approach to identify potential important parameters that distinguish these unique participant groups.
Interestingly, the unsupervised analysis identified a unique cluster of HIV controllers that maintained low CD8 þ T-cell activation despite robust Gag-specific T-cell responses, representing a potentially attractive model for functional cure. In the CD4 þ T-cell compartment, we also found that although controllers and responders had similar percentages of CD4 þ T cells that were activated (CD38þ HLADRþ), controllers had lower percentages of CD4 þ central memory T cells that were activated (HLA-DRþ). It is interesting to note that in this respect HIV controllers are the group most similar to HIV negatives. Further we found that HIV controllers had the highest median percentage of CD4 þ T cells that were resting (CD38À HLADRÀ) central memory cells and CCR5þ.
Similar to other studies [41] , we found a higher proportion of patients who reported black ethnicity as well as a higher proportion of women in the controller group. Elite cluster B (Fig. 1) was enriched for the black ethnicity, the proportion not statistically different from cluster A. However, this could be because of sample size issues. Further larger studies are needed.
We then evaluated the immunological differences in patients on ARTwho failed to have sustained increases in CD4 þ T-cell counts. Consistent with previous studies [42] , we found that most of the group-specific characteristics were in the CD4 þ T-cell compartment. One of most striking and consistent correlates was the expression of PD-1 on CD4 þ T cells, including CD4 þ central memory T cells [43] . Similarly, the percentage of CD4 þ cells expressing TNFa and IFNg was higher in immunologic nonresponders. The expression of activation markers CD38 and HLA-DR was markedly elevated on all CD4 þ T-cell subsets as well as naive CD8 þ T cells, confirming prior observations [44] [45] [46] . Nonresponders also had a lower percentage of naïve CD4 þ T cells. These markers gave excellent prediction results in classifying patients who were nonresponders. It is interesting to note that nonresponders clustered into two groups. One of these groups (group E), in particular was distinct in that it had, on average, lower percentages of activated CD8 þ T cells that expressed CCR5 and higher percentages of central memory CD4 þ T cells. Collectively, these data suggest that ART nonresponse might be because of a combination of factors, including failure to generate new cells and a shorter lifespan (consistent with the expression of activation markers). The markedly elevated levels of PD-1 suggest that many of the T cells are dysfunctional, which might contribute to persistent immunodeficiency and perhaps explain in part the excess morbidity and mortality in this group.
Three limitations of this analysis deserve comment. First, this is a cross-sectional study and has the well recognized limitations of such a design. Specifically, it is difficult to disentangle causality. This is particularly true with regard to our analysis of immunologic nonresponders. Although it is likely that the lack of naïve CD4 þ T cells most likely causes immunologic nonresponse, one could also envision a model in which T-cell activation causes immunologic nonresponse (e.g., by causing excess turnover, or by increasing PD-1 and anergy). A model can also be constructed in which immunologic nonresponse causes T-cell activation (e.g. by persistent immunodeficiency and excess pathogen burden, or by stimulating release of homeostatic signals such as IL-7 that stimulate T-cell proliferation/activation).
A second limitation is that we did not select our participants based on age, sex, or ethnicity; we observed group-to-group differences that might have been mitigated by matching or selection. Notably, the HIV-negative group was younger than the other groups, which may have biased any comparison to the normal state, as age is known to impact immune function. However, we were reassured by the fact that age did not emerge as a key predictor in fuzzy forests algorithms; based on this, age was not included as a potential predictor in the final analysis.
Third, our analysis explored multiple hypotheses, and although random forests theoretically do not over fit, and post hoc comparisons of important variables are generally robust to a Bonferroni-type correction, our results should be interpreted in this light. P values, in general, are not appropriate for machine learning-type applications. Instead, we used OOB error rates. The estimated OOB error rates suggest that our results may be generalizable, although validation studies are needed.
In the current era of widely available, highly effective ART, there is intense interest in understanding immunophenotypes of individuals who achieve undetectable viral load, either naturally or by taking ART. Residual disease during otherwise successful ART is consistently predicted by and possibly caused by persistent inflammation and/or immunodeficiency. There is also intense interest in identifying interventions that will allow durable control of HIV in the absence of therapy. The dataset and approach outlined here clearly points to very distinct groups of 'aviremic' individuals, with at least two distinct groups of immunologic nonresponders and two distinct groups of controllers. It is hoped that further characterization of the heterogeneity within these groups will lead to novel approaches to improve health among those on therapy and perhaps to accelerate discovery of potentially curative interventions.
